Metastatic Surgery in Advanced Renal Cell Carcinoma

  • Laura-Maria Krabbe
  • Solomon L. Woldu
  • Oner Sanli
  • Vitaly Margulis
Living reference work entry

Abstract

Management of patients with advanced and metastatic renal cell carcinoma is a challenging task, which often demands a multidisciplinary approach. In the cytokine immunotherapy era, cytoreductive nephrectomy in combination with immunotherapy was shown to be superior to immunotherapy alone, thus making cytoreductive nephrectomy a cornerstone of treatment. In the more recent era of targeted molecular therapies, cytoreductive nephrectomy seems to still retain its role in management of these patients despite lack of level 1 evidence so far. However, proper patient selection has been shown to be of utmost importance to assure benefit from this surgical endeavor. Prospective trials aiming to inform the field regarding efficacy as well as timing of cytoreductive nephrectomy in the targeted therapy era are underway and eagerly awaited, despite encountering challenges during study enrollment. Additionally, the recent introduction of checkpoint inhibitors once again targeting the immune axis is changing treatment landscape and challenging the benefit of cytoreductive nephrectomy. Metastasectomy on the other hand is currently being utilized for patients with relatively indolent oligometastatic disease. Despite lack of level 1 evidence, available evidence supports long-term remission with metastasectomy for some patients. This chapter aims to summarize the currently available evidence for cytoreductive nephrectomy as well as metastasectomy and give an outlook into the future with regard to new developments in this arena.

References

  1. Abel EJ, Culp SH, et al. Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol. 2011;60(6):1273–9.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Abern MR, Scosyrev E, et al. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res. 2014;34(5):2405–11.PubMedGoogle Scholar
  3. Aizer AA, Urun Y, et al. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int. 2014;113(5b):E67–74.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Alt AL, Boorjian SA, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873–82.PubMedCrossRefGoogle Scholar
  5. Altoos B, Amini A, et al. Local control rates of metastatic renal cell carcinoma (RCC) to thoracic, abdominal, and soft tissue lesions using stereotactic body radiotherapy (SBRT). Radiat Oncol. 2015;10:218.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Alva A, Daniels GA, et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016;65(12):1533–44.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Amendola BE, Wolf AL, et al. Brain metastases in renal cell carcinoma: management with gamma knife radiosurgery. Cancer J. 2000;6(6):372–6.PubMedGoogle Scholar
  8. Amini A, Altoos B, et al. Local control rates of metastatic renal cell carcinoma (RCC) to the bone using stereotactic body radiation therapy: is RCC truly radioresistant? Pract Radiat Oncol. 2015;5(6):e589–96.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Andrews DW, Scott CB, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665–72.PubMedCrossRefGoogle Scholar
  10. Antonelli A, Arrighi N, et al. Surgical treatment of atypical metastasis from renal cell carcinoma (RCC). BJU Int. 2012;110(11 Pt B):E559–63.PubMedCrossRefGoogle Scholar
  11. Aoyama H, Shirato H, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483–91.PubMedCrossRefGoogle Scholar
  12. Assouad J, Petkova B, et al. Renal cell carcinoma lung metastases surgery: pathologic findings and prognostic factors. Ann Thorac Surg. 2007;84(4):1114–20.PubMedCrossRefGoogle Scholar
  13. Bamias A, Tzannis K, et al. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study. Clin Genitourin Cancer. 2014;12(5):373–83.PubMedCrossRefGoogle Scholar
  14. Barbastefano J, Garcia JA, et al. Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. BJU Int. 2010;106(9):1266–9.PubMedCrossRefGoogle Scholar
  15. Barney JD, Churchill EJ. Adenocarcinoma of the kidney with metastasis to the lung cured by nephrectomy and lobectomy. J Urol. 1939;42:269.CrossRefGoogle Scholar
  16. Barnholtz-Sloan JS, Sloan AE, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72.PubMedCrossRefGoogle Scholar
  17. Bex A, Horenblas S, et al. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur Urol. 2002;42(6):570–4. discussion 575–6PubMedCrossRefGoogle Scholar
  18. Bex A, de Bruijn R, et al. Time to targeted therapy after cytoreductive nephrectomy (CN) and surveillance in patients with synchronous unresectable metastases of renal cell carcinoma (RCC). J Clin Oncol. 2016a;34(2 suppl):604.CrossRefGoogle Scholar
  19. Bex A, Ljungberg B, et al. The role of cytoreductive nephrectomy: European Association of Urology recommendations in 2016. Eur Urol. 2016b;70(6):901–5.PubMedCrossRefGoogle Scholar
  20. Bianchi M, Sun M, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23(4):973–80.PubMedCrossRefGoogle Scholar
  21. Borregales LD, Adibi M, et al. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma. Ther Adv Urol. 2016;8(2):130–41.PubMedCrossRefGoogle Scholar
  22. Bruno JJ 2nd, Snyder ME, et al. Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. BJU Int. 2006;97(5):933–8.PubMedCrossRefGoogle Scholar
  23. Carden CP, Larkin JM, et al. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol. 2008;10(4):624–30.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–66.PubMedCrossRefGoogle Scholar
  25. Choueiri TK, Xie W, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–6.PubMedCrossRefGoogle Scholar
  26. ClinicalTrials.gov. Nivolumab and stereotactic ablative radiation therapy (SAbR) for metastatic clear cell renal cell carcinoma. In: Health USNIo, editor. www.clinicaltrials.gov; 2016.
  27. ClinicalTrials.gov. Nivolumab vs nivolumab + bevacizumab vs nivolumab + ipilimumab in metastatic renal cell carcinoma (mRCC) (NCT02210117). 2017a. https://clinicaltrials.gov/ct2/show/NCT02210117?term=cytoreductive+nephrectomy&rank=3. Accessed 3 Feb 2017.
  28. ClinicalTrials.gov. Pazopanib hydrochloride in treating patients with metastatic kidney cancer who have no evidence of disease after surgery. In: Health USNIo, editor. 2017b.Google Scholar
  29. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353(23):2477–90.PubMedCrossRefGoogle Scholar
  30. Conti SL, Thomas IC, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 2014;134(9):2245–52.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Cost NG, Delacroix SE Jr, et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol. 2011;59(6):912–8.PubMedCrossRefGoogle Scholar
  32. Culine S, Bekradda M, et al. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer. 1998;83(12):2548–53.PubMedCrossRefGoogle Scholar
  33. Culp SH, Tannir NM, et al. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer. 2010;116(14):3378–88.PubMedCrossRefGoogle Scholar
  34. Dabestani S, Marconi L, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. Lancet Oncol. 2014;15(12):e549–61.PubMedCrossRefGoogle Scholar
  35. De Meerleer G, Khoo V, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15(4):e170–7.PubMedCrossRefGoogle Scholar
  36. Dekernion JB, Ramming KP, et al. The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol. 1978;120(2):148–52.PubMedCrossRefGoogle Scholar
  37. Dengina N, Tsimafeyeu I, et al. Current role of radiotherapy for renal-cell carcinoma: review. Clin Genitourin Cancer. 2016 Sep;15(2):183–7.PubMedCrossRefGoogle Scholar
  38. Ebele JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumours of the urinary system and male genital organs. World Health Organisation classification of tumours. Lyon: International Agency for Research on Cancer; 2004.Google Scholar
  39. Eggener SE, Yossepowitch O, et al. Risk score and metastasectomy independently impact prognosis of patients with recurrent renal cell carcinoma. J Urol. 2008;180(3):873–8. discussion 878PubMedPubMedCentralCrossRefGoogle Scholar
  40. Escudier B, Eisen T, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125–34.PubMedCrossRefGoogle Scholar
  41. Esrig D, Ahlering TE, et al. Experience with fossa recurrence of renal cell carcinoma. J Urol. 1992;147(6):1491–4.PubMedCrossRefGoogle Scholar
  42. Evenski A, Ramasunder S, et al. Treatment and survival of osseous renal cell carcinoma metastases. J Surg Oncol. 2012;106(7):850–5.PubMedCrossRefGoogle Scholar
  43. Fallick ML, McDermott DF, et al. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol. 1997;158(5):1691–5.PubMedCrossRefGoogle Scholar
  44. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon: International Agency for Research on Cancer; 2014.Google Scholar
  45. Flanigan RC, Salmon SE, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345(23):1655–9.PubMedCrossRefGoogle Scholar
  46. Flanigan RC, Mickisch G, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171(3):1071–6.PubMedCrossRefGoogle Scholar
  47. Fokas E, Henzel M, et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol. 2010;186(4):210–7.PubMedCrossRefGoogle Scholar
  48. Fuchs B, Trousdale RT, et al. Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop Relat Res. 2005;(431):187–92.Google Scholar
  49. Fyfe G, Fisher RI, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96.PubMedCrossRefGoogle Scholar
  50. Gershman B, Moreira DM, et al. Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy. Eur Urol. 2016;69(1):84–91.PubMedCrossRefGoogle Scholar
  51. Gershman B, Thompson RH, et al. Lymph node dissection is not associated with improved survival among patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma: a propensity score based analysis. J Urol. 2017;197(3 Pt 1):574–9.PubMedCrossRefGoogle Scholar
  52. Ghavamian R, Klein KA, et al. Renal cell carcinoma metastatic to the pancreas: clinical and radiological features. Mayo Clin Proc. 2000;75(6):581–5.PubMedCrossRefGoogle Scholar
  53. de Groot S, Redekop WK, et al. Survival in patients with primary metastatic renal cell carcinoma treated with sunitinib with or without previous cytoreductive nephrectomy: results from a population-based registry. Urology. 2016;95:121–7.PubMedCrossRefGoogle Scholar
  54. Guha N, Loomis D, et al. Carcinogenicity of trichloroethylene, tetrachloroethylene, some other chlorinated solvents, and their metabolites. Lancet Oncol. 2012;13(12):1192–3.PubMedCrossRefGoogle Scholar
  55. Haas NB, Manola J, et al. Initial results from ASSURE (E2805): adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. ASCO Meet Abstr. 2015;33(7 suppl):403.Google Scholar
  56. Han KR, Pantuck AJ, et al. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology. 2003;61(2):314–9.PubMedCrossRefGoogle Scholar
  57. Hanna N, Sun M, et al. Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a National Cancer Database study. J Clin Oncol. 2016;34(27):3267–75.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Hanzly M, Aboumohamed A, et al. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience. Urology. 2014;83(5):1129–34.PubMedCrossRefGoogle Scholar
  59. Harada Y, Nonomura N, et al. Clinical study of brain metastasis of renal cell carcinoma. Eur Urol. 1999;36(3):230–5.PubMedCrossRefGoogle Scholar
  60. Heng DY, Xie W, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9.PubMedCrossRefGoogle Scholar
  61. Heng DY, Xie W, et al. External validation and comparison with other models of the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14(2):141–8.PubMedPubMedCentralCrossRefGoogle Scholar
  62. Heng DY, Choueiri TK, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014a;25(1):149–54.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Heng DY, Wells JC, et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014b;66(4):704–10.PubMedCrossRefGoogle Scholar
  64. Hirano D, Okada Y, et al. Intravesical recurrence after surgical management of urothelial carcinoma of the upper urinary tract. Urol Int. 2012;89(1):71–7.PubMedCrossRefGoogle Scholar
  65. Hofmann HS, Neef H, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005;48(1):77–81. discussion 81–2PubMedCrossRefGoogle Scholar
  66. Hudes G, Carducci M, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271–81.PubMedCrossRefGoogle Scholar
  67. Hunt JD, van der Hel OL, et al. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005;114(1):101–8.PubMedCrossRefGoogle Scholar
  68. Hunter GK, Balagamwala EH, et al. The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Pract Radiat Oncol. 2012;2(4):e95–e100.PubMedCrossRefGoogle Scholar
  69. Iacovelli R, Lanoy E, et al. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma. BJU Int. 2012;110(11):1747–53.PubMedCrossRefGoogle Scholar
  70. Ikushima H, Tokuuye K, et al. Fractionated stereotactic radiotherapy of brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2000;48(5):1389–93.PubMedCrossRefGoogle Scholar
  71. Itano NB, Blute ML, et al. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol. 2000;164(2):322–5.PubMedCrossRefGoogle Scholar
  72. Janowitz T, Welsh SJ, et al. Adjuvant therapy in renal cell carcinoma – past, present, and future. Semin Oncol. 2013;40(4):482–91.PubMedPubMedCentralCrossRefGoogle Scholar
  73. Jonasch E, Wood CG, et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(25):4076–81.PubMedPubMedCentralCrossRefGoogle Scholar
  74. Kader AK, Tamboli P, et al. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol. 2007;177(3):855–60. discussion 860–1PubMedCrossRefGoogle Scholar
  75. Kane CJ, Mallin K, et al. Renal cell cancer stage migration: analysis of the National Cancer Database. Cancer. 2008;113(1):78–83.PubMedCrossRefGoogle Scholar
  76. Kanzaki R, Higashiyama M, et al. Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. Eur J Cardiothorac Surg. 2011;39(2):167–72.PubMedCrossRefGoogle Scholar
  77. Karakiewicz PI, Briganti A, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007;25(11):1316–22.PubMedCrossRefGoogle Scholar
  78. Kavolius JP, Mastorakos DP, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261–6.PubMedCrossRefGoogle Scholar
  79. Kawashima A, Nakayama M, et al. Pulmonary metastasectomy in patients with renal cell carcinoma: a single-institution experience. Int J Clin Oncol. 2011;16(6):660–5.PubMedCrossRefGoogle Scholar
  80. Kierney PC, van Heerden JA, et al. Surgeon’s role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol. 1994;1(4):345–52.PubMedCrossRefGoogle Scholar
  81. Kitamura H, Takahashi A, et al. Molecular-targeted therapy and surgery may prolong survival of renal cell carcinoma patients with bone metastasis: a multi-institutional retrospective study in Japan. Anticancer Res. 2016;36(10):5531–6.PubMedCrossRefGoogle Scholar
  82. Kletscher BA, Qian J, et al. Prospective analysis of the incidence of ipsilateral adrenal metastasis in localized renal cell carcinoma. J Urol. 1996;155(6):1844–6.PubMedCrossRefGoogle Scholar
  83. Kollender Y, Bickels J, et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol. 2000;164(5):1505–8.PubMedCrossRefGoogle Scholar
  84. Kucerova P, Cervinkova M. Spontaneous regression of tumour and the role of microbial infection – possibilities for cancer treatment. Anti-Cancer Drugs. 2016;27(4):269–77.PubMedPubMedCentralCrossRefGoogle Scholar
  85. Kuczyk M, Wegener G, et al. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer. Eur Urol. 2005;48(2):252–7.PubMedCrossRefGoogle Scholar
  86. Kutikov A, Uzzo RG, et al. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int. 2010;106(2):218–23.PubMedCrossRefGoogle Scholar
  87. Kwak C, Park YH, et al. Metastasectomy without systemic therapy in metastatic renal cell carcinoma: comparison with conservative treatment. Urol Int. 2007;79(2):145–51.PubMedCrossRefGoogle Scholar
  88. Lara PN Jr, Tangen CM, et al. Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949. J Urol. 2009;181(2):512–6. discussion 516–7PubMedCrossRefGoogle Scholar
  89. Lee SE, Kwak C, et al. Metastatectomy prior to immunochemotherapy for metastatic renal cell carcinoma. Urol Int. 2006;76(3):256–63.PubMedCrossRefGoogle Scholar
  90. Lee JY, Kim CK, et al. Volume doubling time and growth rate of renal cell carcinoma determined by helical CT: a single-institution experience. Eur Radiol. 2008;18(4):731–7.PubMedCrossRefGoogle Scholar
  91. Leibovich BC, Blute ML, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663–71.PubMedCrossRefGoogle Scholar
  92. Li H, Samawi H, et al. The use of prognostic factors in metastatic renal cell carcinoma. Urol Oncol. 2015;33(12):509–16.PubMedCrossRefGoogle Scholar
  93. Lokich J. Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol. 1997;20(4):416–8.PubMedCrossRefGoogle Scholar
  94. Lowrance WT, Ordonez J, et al. CKD and the risk of incident cancer. J Am Soc Nephrol. 2014;25(10):2327–34.PubMedPubMedCentralCrossRefGoogle Scholar
  95. Majewski W, Tabor M, et al. The efficacy of stereotactic radiotherapy for metastases from renal cell carcinoma. Neoplasma. 2016;63(1):99–106.PubMedCrossRefGoogle Scholar
  96. Margulis V, Matin SF, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180(1):94–8.PubMedCrossRefGoogle Scholar
  97. Margulis V, McDonald M, et al. Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. J Urol. 2009;181(5):2044–51.PubMedCrossRefGoogle Scholar
  98. Margulis V, Shariat SF, et al. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol. 2013;63(5):947–52.PubMedCrossRefGoogle Scholar
  99. Mathieu R, Pignot G, et al. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol. 2015;33(8):339.e9–e15.CrossRefGoogle Scholar
  100. McDermott DF, Regan MM, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23(1):133–41.PubMedCrossRefGoogle Scholar
  101. McKay RR, Kroeger N, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65(3):577–84.PubMedCrossRefGoogle Scholar
  102. Mehta MP, Tsao MN, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2005;63(1):37–46.PubMedCrossRefGoogle Scholar
  103. Meimarakis G, Angele M, et al. Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. Am J Surg. 2011;202(2):158–67.PubMedCrossRefGoogle Scholar
  104. Mickisch GH, Garin A, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.PubMedCrossRefGoogle Scholar
  105. Mitchell AP, Hirsch BR, et al. Deferred systemic therapy in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015;13(3):e159–66.PubMedCrossRefGoogle Scholar
  106. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol. 1953;26(305):234–41.PubMedCrossRefGoogle Scholar
  107. Motzer RJ, Bander NH, et al. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865–75.PubMedCrossRefGoogle Scholar
  108. Motzer RJ, Mazumdar M, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–40.PubMedCrossRefGoogle Scholar
  109. Motzer RJ, Bacik J, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289–96.PubMedCrossRefGoogle Scholar
  110. Motzer RJ, Hutson TE, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.PubMedCrossRefGoogle Scholar
  111. Motzer RJ, Escudier B, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56.PubMedCrossRefGoogle Scholar
  112. Motzer RJ, Escudier B, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.PubMedPubMedCentralCrossRefGoogle Scholar
  113. Murthy SC, Kim K, et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg. 2005;79(3):996–1003.PubMedCrossRefGoogle Scholar
  114. Negrier S, Escudier B, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med. 1998;338(18):1272–8.PubMedCrossRefGoogle Scholar
  115. Negrier S, Perol D, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007;110(11):2468–77.PubMedCrossRefGoogle Scholar
  116. Nunez Bragayrac L, Hoffmeyer J, et al. Minimally invasive cytoreductive nephrectomy: a multi-institutional experience. World J Urol. 2016;34(12):1651–6.PubMedCrossRefGoogle Scholar
  117. Oliver RT, Nethersell AB, et al. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989;63(2):128–31.PubMedCrossRefGoogle Scholar
  118. Pantuck AJ, Belldegrun AS, et al. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med. 2001;345(23):1711–2.PubMedCrossRefGoogle Scholar
  119. Park SS, Dong H, et al. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3(6):610–9.PubMedPubMedCentralCrossRefGoogle Scholar
  120. Patard JJ, Kim HL, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22(16):3316–22.PubMedCrossRefGoogle Scholar
  121. Petrelli F, Coinu A, et al. Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis. Clin Genitourin Cancer. 2016;14(6):465–72.PubMedCrossRefGoogle Scholar
  122. Pfannschmidt J, Hoffmann H, et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 2002;74(5):1653–7.PubMedCrossRefGoogle Scholar
  123. Pierorazio PM, McKiernan JM, et al. Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed. BJU Int. 2007;100(4):755–9.PubMedCrossRefGoogle Scholar
  124. Piltz S, Meimarakis G, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg. 2002;73(4):1082–7.PubMedCrossRefGoogle Scholar
  125. van der Poel HG, Roukema JA, et al. Metastasectomy in renal cell carcinoma: a multicenter retrospective analysis. Eur Urol. 1999;35(3):197–203.PubMedCrossRefGoogle Scholar
  126. Procopio G, Verzoni E, et al. Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases. Tumori. 2014;100(1):e28–30.PubMedGoogle Scholar
  127. Psutka SP, Kim SP, et al. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization. Urology. 2015;85(2):442–50.PubMedCrossRefGoogle Scholar
  128. Ranck MC, Golden DW, et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol. 2013;36(6):589–95.PubMedCrossRefGoogle Scholar
  129. Ravaud A, Motzer RJ, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246–54.PubMedCrossRefGoogle Scholar
  130. Reddy S, Wolfgang CL. The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol. 2009;10(3):287–93.PubMedCrossRefGoogle Scholar
  131. Renehan AG, Tyson M, et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.PubMedCrossRefGoogle Scholar
  132. Rini BI, Dorff TB, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016;17(9):1317–24.PubMedCrossRefGoogle Scholar
  133. Robin HI, AuBuchon J, et al. The abscopal effect: demonstration in lymphomatous involvement of kidneys. Med Pediatr Oncol. 1981;9(5):473–6.PubMedCrossRefGoogle Scholar
  134. Robson CJ, Churchill BM, et al. The results of radical nephrectomy for renal cell carcinoma. Trans Am Assoc Genitourin Surg. 1968;60:122–9.PubMedGoogle Scholar
  135. Rothermundt C, Hader C, et al. Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancer. Ann Oncol. 2016;27(3):544–5.PubMedCrossRefGoogle Scholar
  136. Russo P, Synder M, et al. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. ScientificWorldJournal. 2007;7:768–78.PubMedCrossRefGoogle Scholar
  137. Samlowski WE, Majer M, et al. Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery. Cancer. 2008;113(9):2539–48.PubMedCrossRefGoogle Scholar
  138. Sanli O, Zorba OU, et al. Microscopic venous invasion is associated with disease free and cancer free survival in renal cell carcinoma. Minerva Urol Nefrol. 2010;62(4):347–53.PubMedGoogle Scholar
  139. Schoggl A, Kitz K, et al. Gamma-knife radiosurgery for brain metastases of renal cell carcinoma: results in 23 patients. Acta Neurochir. 1998;140(6):549–55.PubMedCrossRefGoogle Scholar
  140. Shuch B, La Rochelle JC, et al. Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer. 2008;113(6):1324–31.PubMedCrossRefGoogle Scholar
  141. Siemer S, Lehmann J, et al. Adrenal metastases in 1635 patients with renal cell carcinoma: outcome and indication for adrenalectomy. J Urol. 2004;171(6 Pt 1):2155–9. discussion 9PubMedCrossRefGoogle Scholar
  142. Smaldone MC, Handorf E, et al. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database. J Urol. 2015;193(4):1108–13.PubMedCrossRefGoogle Scholar
  143. Smith EM, Kursh ED, et al. Treatment of osseous metastases secondary to renal cell carcinoma. J Urol. 1992;148(3):784–7.PubMedCrossRefGoogle Scholar
  144. Stewart GD, Aitchison M, et al. Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may never be answered. Eur Urol. 2016;71(6):845–7.PubMedCrossRefGoogle Scholar
  145. Tanguay S, Pisters LL, et al. Therapy of locally recurrent renal cell carcinoma after nephrectomy. J Urol. 1996;155(1):26–9.PubMedCrossRefGoogle Scholar
  146. Tosco L, Van Poppel H, et al. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Eur Urol. 2013;63(4):646–52.PubMedCrossRefGoogle Scholar
  147. Tsao CK, Small AC, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 2013;31(6):1535–9.PubMedCrossRefGoogle Scholar
  148. Tsui KH, Shvarts O, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163(4):1090–5. quiz 295PubMedCrossRefGoogle Scholar
  149. Vajdic CM, McDonald SP, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31.PubMedCrossRefGoogle Scholar
  150. Wagner JR, Walther MM, et al. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place. J Urol. 1999;162(1):43–5.PubMedCrossRefGoogle Scholar
  151. Walther MM, Alexander RB, et al. Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology. 1993;42(3):250–7. discussion 257–8PubMedCrossRefGoogle Scholar
  152. Walther MM, Yang JC, et al. Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol. 1997;158(5):1675–8.PubMedCrossRefGoogle Scholar
  153. Wersall PJ, Blomgren H, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77(1):88–95.PubMedCrossRefGoogle Scholar
  154. Wersall PJ, Blomgren H, et al. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006;45(4):493–7.PubMedCrossRefGoogle Scholar
  155. Williams AK, Kassouf W, et al. Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urol Oncol. 2013;31(7):1161–5.PubMedCrossRefGoogle Scholar
  156. Winter JM, Cameron JL, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199–210. discussion 210–1PubMedCrossRefGoogle Scholar
  157. Wronski M, Maor MH, et al. External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 1997;37(4):753–9.PubMedCrossRefGoogle Scholar
  158. Yagoda A, Petrylak D, et al. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am. 1993;20(2):303–21.PubMedGoogle Scholar
  159. Yang JC, Sherry RM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21(16):3127–32.PubMedPubMedCentralCrossRefGoogle Scholar
  160. You D, Jeong IG, et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. 2011;185(1):54–9.PubMedCrossRefGoogle Scholar
  161. Zelefsky MJ, Greco C, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1744–8.PubMedCrossRefGoogle Scholar
  162. Zhang S. Adjuvant sunitinib in renal-cell carcinoma. N Engl J Med. 2017;376(9):893.PubMedCrossRefGoogle Scholar
  163. Zisman A, Pantuck AJ, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–57.PubMedCrossRefGoogle Scholar
  164. Znaor A, Lortet-Tieulent J, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–30.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Laura-Maria Krabbe
    • 1
    • 2
  • Solomon L. Woldu
    • 1
  • Oner Sanli
    • 1
  • Vitaly Margulis
    • 1
  1. 1.Department of UrologyUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Department of UrologyUniversity of Muenster Medical CenterMuensterGermany

Section editors and affiliations

  • Mario W. Kramer
    • 1
  • Axel S. Merseburger
    • 2
  1. 1.Klinik für UrologieLübeckGermany
  2. 2.Department of UrologyUniversity Hospital Schleswig-HolsteinLübeckGermany

Personalised recommendations